Congress sets sights on pharma legislation

A bipartisan group of lawmakers introduced a bundle of bills on Thursday designed to empower the Federal Trade Commission to stop branded pharmaceutical companies from delaying market entry of generic competition.


Get unlimited access to all Global Competition Review content